The rapid adoption of GLP-1 receptor agonists is driving significant capital shifts, with global pharmaceutical spending in the metabolic category projected to exceed $100 billion by 2030.
Broader Macroeconomic Ripple Effects
Beyond health outcomes, consumer packaged goods companies are reporting initial shifts in household grocery spend, forcing adjustments in food product formulation and marketing strategies.